Understanding the beneficial effects of doxycycline on the dystrophic phenotype of the mdx mouse

Muscle and Nerve

Volumn 50, Issue 2, 2014, Pages 283-286

  Pereira, Juliano Alves ^a   Matsumura, Cintia Yuri ^a   Minatel, Elaine ^a   Marques, Maria Julia ^a   Neto, Humberto Santo ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Calsequestrin 1; DMD; Doxycycline; mdx; Metalloproteinase 9; TNF

Indexed keywords

CALCIUM; CALSEQUESTRIN; DOXYCYCLINE; DRINKING WATER; GELATINASE B; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BICEPS BRACHII MUSCLE; CONTROLLED STUDY; DIAPHRAGM; DRUG EFFECT; DRUG INHIBITION; FEMALE; MOUSE; MUSCULAR DYSTROPHY; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL;

CALSEQUESTRIN 1; DMD; DOXYCYCLINE; MDX; METALLOPROTEINASE-9; TNF-Α;

ALDEHYDES; ANIMALS; ANTI-BACTERIAL AGENTS; CALCIUM; CALCIUM-BINDING PROTEINS; DOXYCYCLINE; GENE EXPRESSION REGULATION; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, INBRED MDX; MUSCULAR DYSTROPHY, ANIMAL; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904645488     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.24177     Document Type: Article

References (25)

1. Bulfield G, Siller WG, Wight PAL, Moore KJ. X chromosome-liked muscular dystrophy (mdx) in the mouse. Proc Natl Acad Sci USA 1984;81:1189-1192.
2. Engel AG, Yamamoto M, Fischbeck KH. Dystrophinopathies. Engel AG, Franzini-Armstrong C, editors. Myology. Vol. 2. New York: McGraw-Hill; 1994. p 1133-1187.
3. Grounds MD, Torrisi J. Anti-TNF (Remicade) therapy protects dystrophic skeletal muscle from necrosis. FASEB J 2004;18:676-682.
4. Hodgetts S, Radley HG, Davies, M, Grounds MD. Reduced necrosis of dystrophic muscle by depletion of host neutrophils, or blocking TNF alpha function with Etanercept in mdx mice. Neuromuscul Disord 2006;16:591-602.
5. Machado RV, Mauricio AF, Taniguti AP, Ferretti R, Neto HS, Marques MJ. Eicosapentaenoic acid decreases TNF-α and protects dystrophic muscles of mdx mice from degeneration. J Neuroimmunol 2011;232:145-150.
6. Whitehead NP, Yeung EW, Allen DG. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 2006;33:657-662.
7. Nadarajah VD, van Putten M, Chaouch A, Garrood P, Straub V, Lochmüller H, et al. Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD). Neuromuscul Disord 2011;21:569-578.
8. Li H, Mittal A, Makonchuk DY, Bhatnagar S, Kumar A. Matrix metalloproteinase-9 inhibition ameliorates pathogenesis and improves skeletal muscle regeneration in muscular dystrophy. Hum Mol Genet 2009;18:2584-2598.
9. Kumar A, Bhatnagar S, Kumar A. Matrix metalloproteinase inhibitor batimastat alleviates pathology and improves skeletal muscle function in dystrophin-deficient mdx mice. Am J Pathol 2010;177:248-260.
10. Alameddine HS. Matrix metalloproteinases in skeletal muscles: friends or foes? Neurobiol Dis 2012; 48:508-518.
11. Griffin MO, Ceballos G, Villarreal F. Tetracycline compounds with non-antimicrobial organ protective properties: possible mechanisms of action. Pharmacol Res 2011;63:102-107.
12. Minagar A, Alexander JS, Schwendimann RN, Kelley RE, Gonzalez-Toledo E, Jimenez JJ, et al. Combination therapy with interferon beta-1a and doxycycline in multiple sclerosis: an open-label trial. Arch Neurol 2008;65:199-204.
13. Brown DL, Desai KK, Vakili BA, Nouneh C, Lee HM, Golub LM. Clinical and biochemical results of the metalloproteinase inhibition with subantimicrobial doses of doxycycline to prevent acute coronary syndromes (MIDAS) pilot trial. Arterioscler Thromb Vasc Biol 2004;24:733-738.
14. Lindeman JH, Abdul-Hussien H, van Bockel JH, Wolterbeek R, Kleemann R. Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells. Circulation 2009;119:2209-2216.
15. Pereira JA, Taniguti APT, Matsumura C, Marques MJ, Santo Neto H. Doxycycline ameliorates the dystrophic phenotype of skeletal and cardiac muscles in mdx mice. Muscle Nerve 2012;46:400-406.
16. Bhatnagar S, Kumar A. Therapeutic targeting of signaling pathways in muscular dystrophy. J Mol Med 2010;88:155-166.
17. Terrill JR, Boyatzis A, Grounds MD, Arthur PG. Treatment with the cysteine precursorl-2-oxothiazolidine-4-carboxylate (OTC) implicates taurine deficiency in severity of dystropathology in mdx mice. Int J Biochem Cell 2013;45:2097-2108.
18. Fogagnolo AM, Minatel E, Santo Neto H, Marques MJ. Effects of fish oil containing eicosapentaenoic acid and docosahexaenoic acid on dystrophic mdx mice. Clin Nutr 2013;32:636-642.
19. Matsumura CY, Pertille A, Albuquerque TCP, Santo Neto H, Marques MJ. Diltiazem and verapamil protect dystrophin-deficient muscle fibers of mdx mice from degeneration: a potential role in calcium buffering and sarcolemmal stability. Muscle Nerve 2009;39:167-176.
20. Lau AC, Duong TT, Ito S, Wilson GJ, Yeung RSM. Inhibition of matrix metalloproteinase-9 improves coronary outcome in an animal model of Kawasaki disease. Clin Exp Immunol 2009;157:300-309.
21. Srivastava AK, Qin X, Wedhas N, Arnush M, Linkhart TA, Chadwick RB, et al. Tumor necrosis factor-alpha augments matrix metalloproteinase-9 production in skeletal muscle cells through the activation of transforming growth factor-beta-activated kinase 1 (TAK1)-dependent signaling pathway. J Biol Chem 2007;282:35113-35124.
22. Uchida K. 4-Hydroxy-2-nonenal; a product and mediator of oxidative stress. Prog Lipid Res 2003;42:318-343.
23. Nelson ML. Chemical and biological dynamics of tetracyclines. Adv Dent Res 1998;12:5-11.
24. Novák P, Soukup T. Calsequestrin distribution, structure and function, its role in normal and pathological situations and the effect of thyroid hormones. Physiol Res 2011;60:439-452.
25. Seok J, Shaw Warren H, Cuenca AG, Mindrinos MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci USA 2013;110:3507-3512.